Capricorn resignations a blow to New Med merger plans
The disputed deal is playing out in public, as Capricorn’s board and activist shareholder Palliser both issue statements and rebuttals
The proposed merger of London-listed Capricorn Energy and Israel’s Newmed may have been scuppered by shareholder opposition. Five of the Capricorn board’s nine members resigned in late January, including the chairman and CEO. Another two board members, including the CFO, have committed to resign before 1 February. That is when shareholders will meet—as requested by shareholder and London-based fund Palliser Capital—to approve replacement board members, instead of voting on the merger deal, as was previously scheduled. The merger vote itself has now been pushed back to 22 February, which Capricorn says will allow “a reconstituted board to assess the proposed Newmed combination alongside other
Also in this section
26 April 2024
While the US has been breaking records for its premium grade crude, there are doubts over whether you can have too much of a good thing
26 April 2024
Slowing demand growth and capacity expansions will squeeze refiners in coming years
25 April 2024
Some companies with assets in Israel have turned towards Egypt as tensions escalate, but others are holding firm despite rising tensions
24 April 2024
But even planned exploration activity is unlikely to reverse declining output from mature fields